Physician

Boris Bagdasarian, D.O.

According to 2025 Medicare claims, Boris Bagdasarian, D.O. (NPI: 1598758062) practices hematology/oncology in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. This provider's primary affiliated billing organization is LOS ANGELES HEMATOLOGY-ONCOLOGY MEDICAL GROUP (NPI: 1457409674; TIN: 95-4332724) and primary practice location at 91206-4073.

Bagdasarian's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,041 traditional Medicare patients, billed 285,154 HCPCS/CPT codes, and received $7,782,866 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,271 prescription claims across 407 beneficiaries totaling $15,643,281 in drug costs, led by Xtandi (Enzalutamide). DME data shows 224 claims. Open Payments data shows 247 records totaling $6,426. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,903,812 and ending at $7,782,866. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $4,137,637 to $15,643,281. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $2,607 to $147.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	697	198,872	$1,903,812
2016	821	503,996	$2,218,547
2017	888	436,042	$2,693,791
2018	1,050	541,079	$3,547,217
2019	1,045	513,432	$3,516,293
2020	952	470,160	$4,312,121
2021	961	214,083	$2,809,190
2022	1,048	124,277	$1,991,968
2023	1,124	161,870	$2,779,291
2024	1,041	285,154	$7,782,866

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	301	2,552	$4,137,637
2016	341	2,749	$4,899,788
2017	380	2,995	$5,429,182
2018	396	3,796	$9,152,995
2019	417	3,752	$11,575,159
2020	413	4,163	$12,120,134
2021	457	6,090	$16,906,012
2022	493	6,751	$20,560,177
2023	438	6,335	$23,642,935
2024	407	3,271	$15,643,281

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	43	162	$91,061
2016	49	149	$73,745
2017	25	138	$35,839
2018	41	103	$16,817
2019	67	240	$26,864
2020	58	166	$15,856
2021	58	252	$16,538
2022	64	304	$30,411
2023	86	296	$61,380
2024	33	224	$7,020

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	648	2,767	$105
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	494	1,046	$72
36415	Insertion of needle into vein for collection of blood sample	655	2,184	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	626	2,446	$8
96127	Assessment of emotional or behavioral problems	737	1,485	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	155	4,650	$2,096,177
Kisqali	Ribociclib Succinate	113	3,143	$1,731,678
Ibrance	Palbociclib	100	2,800	$1,580,887
Tagrisso	Osimertinib Mesylate	50	1,500	$969,880
Revlimid	Lenalidomide	56	1,512	$968,855

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	41	$2,144
J8521	Capecitabine, oral, 500 mg	N	14	49	$1,586
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	19	61	$1,129
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	13	$1,029
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	16	$567

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	247	$6,426	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Boris Bagdasarian, D.O.?

Tedicare shows public-source Medicare data for Boris Bagdasarian, D.O. (NPI 1598758062), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Boris Bagdasarian, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Boris Bagdasarian, D.O.?

Boris Bagdasarian, D.O. is linked to LOS ANGELES HEMATOLOGY-ONCOLOGY MEDICAL GROUP (billing NPI 1457409674) in the available physician profile data.

Does Boris Bagdasarian, D.O. have Open Payments data?

Boris Bagdasarian, D.O. has 247 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.